June 1, 2009 - Generex Biotechnology Corporation announced today that the results of a recently completed Phase I trial in prostate cancer patients of the novel immunotherapeutic peptide AE37 were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Fla., from May 29 to June 2, 2009.

The studies were conducted in Athens, Greece under the direction of medical doctor Constantin Baxevanis. The immunotherapeutic peptide AE37 is being developed by Antigen Express Inc., a wholly-owned subsidiary of Generex, for multiple cancer indications.

The study, entitled "Results from the First Phase I Clinical Study of the Novel Ii-Key/HER-2/neu (776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer," reports on both the safety and immunological response to the vaccine in patients. The trial demonstrated that the vaccine is safe, well tolerated and produces the desired immunological response in patients. The results of this study are consistent with those of prior clinical trials of AE37 in patients with breast cancer. AE37 is currently the subject of a randomized phase II clinical trial in patients with node positive or high risk node negative breast cancer as well as an additional phase I trial wherein it is being studied in combination with another immunotherapeutic peptide.

For more information: www.generex.com


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now